Literature DB >> 8642353

Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.

N Gervois1, Y Guilloux, E Diez, F Jotereau.   

Abstract

Coculture of melanoma cells and T cell clones derived from tumor-infiltrating lymphocytes (TIL) generally results in lysis of the antigen-bearing tumor cells but to inefficient proliferation and IL-2 secretion by responder T cells. This suboptimal activation is classically explained by an inability of tumor cells to provide costimulatory signals. Here we analyzed the responses to synthetic peptides of HLA-A2.1-restricted CTL clones specific for melanoma antigens MART-1 and NA17-A. We showed that peptide concentrations ranging from 1 pM to 10 nM efficiently sensitized the peptide transporter-deficient T2 cells to lysis. T2 cells pulsed with melanoma peptides also induced TIL proliferation and detectable secretion of IL-2, IFN-gamma and GM-CSF, but only for peptide concentrations 10- to 10,000-fold higher than those required for lysis. Hence this suggests that partial triggering of TIL clones by melanoma cells could be due to expression of appropriate MHC-peptide complexes at subthreshold levels. In support of this, we showed that melanoma cells, unable to trigger IL-2 secretion, developed this ability when incubated with the appropriate peptide. These results indicate that the level of antigens expressed on melanoma tumors critically affects TIL activation status and thus, the efficiency of specific immune reactions mediated by these cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642353      PMCID: PMC2192543          DOI: 10.1084/jem.183.5.2403

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  12 in total

Review 1.  New perspectives of CD28-B7-mediated T cell costimulation.

Authors:  J A Bluestone
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

2.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.

Authors:  R D Salter; D N Howell; P Cresswell
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

3.  Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.

Authors:  M C Pandolfino; C Viret; N Gervois; Y Guilloux; F Davodeau; E Diez; F Jotereau
Journal:  Eur J Immunol       Date:  1992-07       Impact factor: 5.532

4.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Authors:  Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; L Rivoltini; S L Topalian; T Miki; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

5.  Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes.

Authors:  C Traversari; P van der Bruggen; B Van den Eynde; P Hainaut; C Lemoine; N Ohta; L Old; T Boon
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

6.  Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.

Authors:  C Viret; F Davodeau; Y Guilloux; J D Bignon; G Semana; R Breathnach; F Jotereau
Journal:  Eur J Immunol       Date:  1993-01       Impact factor: 5.532

7.  T cell activation by antigens on human melanoma cells--co-stimulation by B7-1 is neither sufficient nor necessary to stimulate IL-2 secretion by melanoma-specific T cell clones in vitro.

Authors:  C Viret; N Gervois; Y Guilloux; E Le Dréan; E Diez; F Jotereau
Journal:  Int Immunol       Date:  1995-10       Impact factor: 4.823

8.  Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.

Authors:  Y Guilloux; C Viret; N Gervois; E Le Dréan; M C Pandolfino; E Diez; F Jotereau
Journal:  Eur J Immunol       Date:  1994-09       Impact factor: 5.532

Review 9.  The B7 and CD28 receptor families.

Authors:  C H June; J A Bluestone; L M Nadler; C B Thompson
Journal:  Immunol Today       Date:  1994-07

10.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  P G Coulie; V Brichard; A Van Pel; T Wölfel; J Schneider; C Traversari; S Mattei; E De Plaen; C Lurquin; J P Szikora; J C Renauld; T Boon
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  19 in total

1.  Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.

Authors:  Sourabh Ghosh; Rachel Rosenthal; Paul Zajac; Walter P Weber; Daniel Oertli; Michael Heberer; Ivan Martin; Giulio C Spagnoli; Anca Reschner
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

2.  Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.

Authors:  Shannon K Oda; Pamela Strauch; Yuko Fujiwara; Amin Al-Shami; Tamas Oravecz; Gabor Tigyi; Roberta Pelanda; Raul M Torres
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

3.  Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells.

Authors:  John J Engelhardt; Bijan Boldajipour; Peter Beemiller; Priya Pandurangi; Caitlin Sorensen; Zena Werb; Mikala Egeblad; Matthew F Krummel
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

4.  Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptides.

Authors:  L Toujas; J G Delcros; E Diez; N Gervois; G Semana; G Corradin; F Jotereau
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

5.  Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen.

Authors:  H Höhn; C Neukirch; K Freitag; A Necker; W Hitzler; B Seliger; M J Maeurer
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 6.  Immune regulation and anti-cancer activity by lipid inflammatory mediators.

Authors:  Saraswoti Khadge; John Graham Sharp; Timothy R McGuire; Geoffrey M Thiele; Paul Black; Concetta DiRusso; Leah Cook; Lynell W Klassen; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2018-11-14       Impact factor: 4.932

7.  An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.

Authors:  P André; M Groettrup; P Klenerman; R de Giuli; B L Booth; V Cerundolo; M Bonneville; F Jotereau; R M Zinkernagel; V Lotteau
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 8.  Mobilizing the low-avidity T cell repertoire to kill tumors.

Authors:  Rachel H McMahan; Jill E Slansky
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

9.  A systemic antitumor immune response prevents outgrowth of lung tumors after i.v. rechallenge but is not able to prevent growth of experimental liver tumors.

Authors:  Frederieke H van Duijnhoven; Remco I J M Aalbers; Joost Rothbarth; Onno T Terpstra; Peter J K Kuppen
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

10.  In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice.

Authors:  Todd D Schell
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.